aap reports Nine-Month Sales of EUR 24.2 million (+30%) and EBIT of EUR 1.3 million (+16%)

aap Implantate AG, a medical technology company listed on the Frankfurt Stock Exchange in the Prime Standard segment and active in medical biomaterials, fracture healing and joint replacement, achieved a 30% growth in sales in the first nine months of the financial year 2008 to EUR 24.2 million (previous year: EUR 18.6 million). This is based primarily on the disproportionately positive business development of the Traumatology & Orthopaedics (aap T&O) division, where sales growth in the past three quarters has been around 57% higher than last year. The Group operating result rose from EUR 1.1 million to EUR 1.3 million.

In the first three quarters of 2008 the Group earned an EBITDA of EUR 3.7 million (previous year: EUR 2.7 million). Group EBIT was EUR 1.3 million (previous year: EUR 1.1 million) and EBT EUR 0.6 million (previous year: EUR 0.8 million). With total assets of EUR 74.0 million (previous year: EUR 63.7 million) the equity ratio after entry of the capital increase in the Commercial Register was 63%.

Highlights of the third Quarter 2008 were the successfully placed 5% capital increase and the signing of an agreement with Zimmer Holdings Inc. on the distribution of the EASYMIX® vacuum mixing system.

For 2008 aap anticipates furthermore an organic sales growth of more than 20%.